Can a simple inhaled antibiotic stop ventilator pneumonia?

NCT ID NCT06834971

Recruiting now Prevention Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether inhaling an antibiotic called colistin can prevent ventilator-associated pneumonia (VAP) in ICU patients at high risk for drug-resistant infections. About 508 adults on breathing machines for at least two days will receive either colistin or a placebo via nebulizer for three days. The goal is to see if this short treatment lowers the number of patients who develop VAP within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colistin (an antibiotic)
What this could lead to: If it works, this could offer a simple way to prevent a serious lung infection in ICU patients on breathing machines.
What could go wrong: This is an early-stage trial with 508 participants, so results may not apply to all patients. Colistin can cause kidney or nerve problems, and the infection may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTILATOR-ASSOCIATED PNEUMONIA (VAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTILATOR-ASSOCIATED PNEUMONIA (VAP)

Contacts and locations

Locations

Qilu Hospital of Shandong university
RECRUITING

Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.